PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsIpatasertib
Ipatasertib
Ipatasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-beta serine/threonine-protein kinase, RAC-gamma serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase. In addition, it is known to target cGMP-dependent protein kinase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
56 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C507113——18
Prostatic neoplasmsD011471—C61341——6
Triple negative breast neoplasmsD064726——241——5
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8054———8
Ovarian neoplasmsD010051EFO_0003893C5623———5
Stomach neoplasmsD013274EFO_0003897C16—3———3
Non-small-cell lung carcinomaD002289——13———3
Endometrial neoplasmsD016889EFO_0004230—12———2
Castration-resistant prostatic neoplasmsD064129——21———2
GlioblastomaD005909EFO_0000515—22———2
Squamous cell carcinoma of head and neckD000077195——11———2
Oropharyngeal neoplasmsD009959——11———2
Laryngeal neoplasmsD007822EFO_0003817C3211———2
Show 21 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———3————3
Hepatic insufficiencyD048550——1————1
Squamous cell carcinomaD002294——1————1
Fallopian tube neoplasmsD005185——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIpatasertib
INNipatasertib
Description
(2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone is a N-arylpiperazine.
Classification
Small molecule
Drug classserine/threonine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1
Identifiers
PDB—
CAS-ID1001264-89-6
RxCUI—
ChEMBL IDCHEMBL2177390
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID524Y3IB4HQ (ChemIDplus, GSRS)
Target
Agency Approved
AKT2
AKT2
AKT3
AKT3
AKT1
AKT1
Organism
Homo sapiens
Gene name
AKT2
Gene synonyms
NCBI Gene ID
Protein name
RAC-beta serine/threonine-protein kinase
Protein synonyms
murine thymoma viral (v-akt) homolog-2, PKB beta, Protein kinase Akt-2, Protein kinase B beta, putative v-akt murine thymoma viral oncoprotein 2, rac protein kinase beta, RAC-PK-beta, v-akt murine thymoma viral oncogene homolog 2
Uniprot ID
Mouse ortholog
Akt2 (11652)
RAC-beta serine/threonine-protein kinase (Q60823)
Alternate
PRKG1
PRKG1
Organism
Homo sapiens
Gene name
PRKG1
Gene synonyms
PRKG1B, PRKGR1A, PRKGR1B
NCBI Gene ID
Protein name
cGMP-dependent protein kinase 1
Protein synonyms
cGKI, cGMP-dependent protein kinase I, protein kinase, cGMP-dependent, regulatory, type I, beta, protein kinase, cGMP-dependent, type I
Uniprot ID
Mouse ortholog
Prkg1 (19091)
cGMP-dependent protein kinase 1 (Q9Z0Z0)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,221 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
90 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use